Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) is the loss of normal ovarian function before age 40 — a condition that affects about 1 in 100 women and arrives, for many, as a complete shock. Unlike natural menopause, which unfolds gradually over years in the early 50s, POI can strike in the 20s or 30s, cutting short the supply of estrogen, progesterone, and testosterone that a young woman's heart, bones, brain, and reproductive system depend on. The name was deliberately changed from "premature ovarian failure" because the ovaries do not always shut down completely: roughly 5 to 10 percent of women with POI conceive spontaneously after diagnosis, when the ovaries briefly reactivate. Understanding what causes POI, what it does to the body over time, and how modern hormone therapy can reverse most of its long-term risks is the foundation of good care.

Table of Contents

  1. What Is Premature Ovarian Insufficiency
  2. Causes — Genetic and Chromosomal
  3. Causes — Autoimmune and Associated Conditions
  4. Causes — Cancer Treatment and Surgery
  5. Symptoms — Estrogen Deficiency and Psychological Impact
  6. Diagnosis — Lab Tests and Genetic Screening
  7. Hormone Replacement Therapy — Why It Differs from Postmenopausal HRT
  8. Estrogen, Progesterone, and Testosterone Specifics
  9. Fertility Options and Family Planning
  10. Psychological Support and Long-Term Wellbeing
  11. Key Research Papers
  12. Connections
  13. Featured Videos

What Is Premature Ovarian Insufficiency

Premature ovarian insufficiency is defined by two criteria occurring together before a woman's 40th birthday: amenorrhea lasting more than four months, and a follicle-stimulating hormone (FSH) level above 25 IU/L on two separate blood tests taken at least four to six weeks apart. The elevated FSH reflects the pituitary gland straining to stimulate ovaries that are no longer responding — the same pattern seen in natural menopause, but arriving one to two decades too early.

The condition is more common than most people realize. Approximately 1 percent of women under 40 are affected; the proportion falls to 0.1 percent under 30 and 0.01 percent under 20. Because it is rare in teenagers and twentysomethings, doctors sometimes mistake the early warning signs — irregular or skipped periods — for stress, low body weight, or polycystic ovary syndrome, and the correct diagnosis is often delayed by three to five years after symptoms begin.

The terminology shift from "premature ovarian failure" or "premature menopause" to POI is medically meaningful. "Failure" implied a permanent, complete shutdown, which is not always true. Women with POI can have intermittent follicular activity; ovulation and even pregnancy can occur unpredictably even years after diagnosis. "Premature menopause" is also inaccurate because it suggests a parallel to the natural menopausal transition, which involves a gradual hormone decline over several years. In POI the drop can be abrupt, especially when caused by surgery or chemotherapy, and it happens at an age when the body still has decades of use for estrogen.

The most important clinical reality distinguishing POI from natural menopause is the duration of estrogen deficiency. A woman who reaches natural menopause at 51 spends roughly 30 years in an estrogen-low state. A woman diagnosed with POI at 28 faces 23 additional estrogen-deficient years before she would have naturally reached menopause. That extended deficit is directly responsible for the elevated lifetime risks of osteoporosis, cardiovascular disease, cognitive decline, and premature mortality that characterize untreated POI — and it is the central reason why hormone replacement therapy is not optional but essential.

Back to Table of Contents

Causes — Genetic and Chromosomal

In 50 to 70 percent of cases, no specific cause can be identified despite thorough investigation — these are classified as idiopathic POI and are believed to reflect undiscovered autoimmune or genetic mechanisms. Of the identifiable causes, genetic and chromosomal factors account for roughly 30 percent.

FMR1 premutation is the single most important genetic cause to identify. The FMR1 gene on the X chromosome normally carries fewer than 45 CGG repeats; a full mutation of more than 200 repeats causes fragile X syndrome, the most common inherited form of intellectual disability. A premutation — between 55 and 200 repeats — produces reduced levels of the FMRP protein and causes POI in approximately 20 to 28 percent of female carriers. The reason this must be tested in every woman with unexplained POI is not only to explain her condition, but because of the family implications: a premutation carrier's daughters may inherit a full expansion and develop fragile X syndrome, and her brothers may develop fragile X-associated tremor/ataxia syndrome. Genetic counseling for the entire family is indicated whenever a premutation is found.

Turner syndrome (45,X monosomy) is the most common genetic cause of POI in adolescents. The absence of a second sex chromosome leads to streak gonads — fibrous remnants that fail to produce estrogen — causing primary amenorrhea, absent puberty, and short stature. Many girls with Turner syndrome are diagnosed before puberty. Variants such as 45,X/46,XX mosaicism produce a milder and more variable picture, including some residual ovarian function and even occasional fertility.

Other X-chromosome defects associated with POI include deletions in the Xq13–Xq26 region, mutations in BMP15 (bone morphogenetic protein 15, which is expressed exclusively in oocytes and regulates follicle development), DIAPH2, and XIST. Among autosomal gene mutations, FOXL2 is notable: mutations cause blepharophimosis-ptosis-epicanthus inversus syndrome, a rare condition in which drooping eyelids accompany POI. FSHR mutations affect the FSH receptor, meaning follicles are present in the ovary but cannot respond to FSH signals — these women have elevated FSH despite a normal-looking ovary on ultrasound. Mutations in NOBOX, NR5A1 (SF-1), and BMPR1B contribute to a smaller fraction of cases.

Galactosemia deserves special mention. This autosomal recessive metabolic disorder causes an inability to process galactose, and galactose-1-phosphate accumulates in ovarian tissue, directly toxic to oocytes. Girls with classic galactosemia develop POI even when they have been on a strict galactose-free diet since infancy, suggesting that the ovarian damage occurs in fetal life or very early childhood before dietary management can protect the ovaries.

Back to Table of Contents

Causes — Autoimmune and Associated Conditions

Autoimmune mechanisms account for approximately 5 to 10 percent of identifiable POI cases, though the true proportion among idiopathic cases is likely higher because not all autoimmune markers have been discovered. The hallmark of autoimmune oophoritis is lymphocytic infiltration of developing follicles, driven by antibodies against steroidogenic cells — the cells within follicles that produce estrogen and progesterone. The ovaries contain growing follicles but the immune system attacks them before they can mature.

The most clinically important autoimmune marker is the anti-21-hydroxylase antibody (also called anti-steroid-cell antibody or adrenal cortex antibody). This antibody is a marker for concurrent autoimmune adrenal disease. Among women with autoimmune POI who test positive for this antibody, roughly 50 percent will develop Addison's disease — autoimmune adrenal insufficiency — within 10 to 15 years of their POI diagnosis. Addison's disease can be life-threatening if an adrenal crisis occurs during illness or surgery without cortisol replacement. For this reason, all women with POI who test positive for anti-21-hydroxylase antibodies should be screened annually with a morning cortisol or ACTH stimulation test.

Thyroid autoimmunity is particularly common in POI: 30 to 40 percent of women with POI carry thyroid peroxidase (TPO) antibodies or thyroglobulin (TgAb) antibodies, and they carry a substantially elevated lifetime risk of developing clinical hypothyroidism. Thyroid function tests and TPO antibodies should be checked at diagnosis and rechecked regularly.

Other autoimmune conditions that cluster with POI include type 1 diabetes mellitus, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, vitiligo, and pernicious anemia. Women with autoimmune polyendocrine syndrome type 1 (APS-1, caused by AIRE mutations) and type 2 (APS-2, Schmidt syndrome) have particularly high rates of POI alongside their adrenal and thyroid autoimmunity. The presence of POI in a young woman should therefore prompt a review for other autoimmune conditions, even if symptoms are subtle.

Back to Table of Contents

Causes — Cancer Treatment and Surgery

Iatrogenic POI — caused by medical treatment — is entirely predictable and, when anticipated, partially preventable. The three main iatrogenic routes are chemotherapy, pelvic radiation, and surgical removal of the ovaries.

Chemotherapy damages the ovarian follicle pool through direct DNA toxicity, primarily by targeting rapidly dividing cells. Alkylating agents are the most gonadotoxic class: cyclophosphamide, busulfan, melphalan, and chlorambucil all carry a high risk of permanent POI, and the risk increases with cumulative dose and with older age at treatment (prepubertal girls retain more follicular reserve than adult women after the same regimen, because they start with a larger pool). Platinum compounds and anthracyclines carry intermediate risk; antimetabolites like methotrexate are low risk but not zero.

Fertility preservation before chemotherapy is now standard of care in guidelines from ASCO, ASRM, and ESHRE. Oocyte or embryo cryopreservation — retrieving eggs via IVF stimulation before chemotherapy begins — is the gold-standard established method with well-documented live birth rates. Ovarian tissue cryopreservation (removing and freezing a slice of ovarian cortex) is increasingly used, particularly in prepubertal girls who cannot undergo egg retrieval, but carries a theoretical risk of reimplanting malignant cells in certain cancers such as leukemia. GnRH agonist co-administration during chemotherapy is widely used to suppress ovarian function and potentially protect follicles, but evidence of benefit remains contested; it is not a substitute for fertility preservation.

Radiation to the pelvis causes dose-dependent ovarian damage. Doses as low as 2 Gy can reduce ovarian reserve, and doses above 8 Gy are associated with permanent POI in most women. Total body irradiation used in bone marrow transplant conditioning carries a very high risk of permanent ovarian failure. Ovarian transposition (oophoropexy) — surgically moving the ovaries outside the radiation field before treatment — can preserve function when the radiation target does not encompass the entire pelvis.

Bilateral oophorectomy for benign conditions — most commonly severe endometriosis, recurrent ovarian cysts, or prophylactic risk reduction in BRCA mutation carriers — causes immediate surgical menopause. Unlike natural menopause, where estrogen declines gradually over years, surgical menopause is abrupt; hot flashes, sleep disruption, and mood changes can begin within days. Long-term cardiovascular and bone consequences are more severe than in spontaneous POI if HRT is not started promptly.

Back to Table of Contents

Symptoms — Estrogen Deficiency and Psychological Impact

The symptoms of POI arise from two sources: the direct physiological effects of estrogen deficiency, and the profound psychological impact of receiving this diagnosis at a young age. Both deserve full attention in clinical care.

Vasomotor symptoms — hot flashes, night sweats, and unpredictable sweating episodes — affect 75 to 80 percent of women with POI. Because the estrogen drop can be more abrupt than in natural menopause, vasomotor symptoms are often more intense and more disruptive. Night sweats fragment sleep, and the resulting fatigue compounds daytime symptoms. Many women describe being woken multiple times per night, leaving them exhausted and cognitively impaired during the day.

Menstrual changes are usually the first sign: cycles become irregular, then infrequent, then absent. Some women have a period of oligomenorrhea lasting months or years before frank amenorrhea; others experience sudden cessation. Because irregular periods are common in young women for many reasons, POI is often not considered until amenorrhea is prolonged.

Genitourinary symptoms — vaginal dryness, painful intercourse (dyspareunia), increased urinary tract infections, and bladder urgency — result from atrophic changes to the vulva, vagina, and lower urinary tract that depend on estrogen for tissue health. These symptoms are underreported because many women feel embarrassed discussing them and because they develop gradually. Without treatment, they are progressive.

Sexual function is affected by multiple converging factors: vaginal atrophy causes dyspareunia; testosterone deficiency (the ovaries normally produce roughly half of a woman's total testosterone) reduces libido and arousal; fatigue from night sweats reduces motivation; and psychological distress from the diagnosis and infertility creates a barrier to intimacy.

Bone and cardiovascular health are the long-term consequences of greatest medical concern. Estrogen is critical to bone density maintenance; in the absence of HRT, women with POI lose bone at an accelerated rate and are at substantially elevated risk of osteoporosis and fragility fractures decades before their peers. Estrogen also protects the cardiovascular system through its effects on endothelial function, lipid profiles, and inflammation. Studies show that women with POI who do not use HRT have impaired endothelial function, higher rates of dyslipidemia, and earlier cardiovascular events. Women who undergo surgical menopause before age 45 without HRT have approximately 1.5 to 2 times the risk of myocardial infarction compared with women reaching natural menopause at 50.

Psychological impact is often the most immediately painful aspect of a POI diagnosis. Depression and anxiety are common, and grief over the loss of natural fertility and the anticipated loss of a "normal" reproductive life can be profound. Women diagnosed in their 20s or 30s often feel profoundly isolated — their peers are not experiencing this, and there is rarely anyone in their immediate social circle who understands. The identity disruption can be severe: womanhood, fertility, and perceived youthfulness are all implicated in a single diagnosis. Cognitive symptoms — difficulty concentrating, word-finding problems, and short-term memory issues — are reported by many women with POI and appear to improve with adequate estrogen replacement.

Back to Table of Contents

Diagnosis — Lab Tests and Genetic Screening

Diagnosing POI requires confirming the hormonal pattern, ruling out pregnancy, and then working through a structured screen for underlying causes. No single test makes the diagnosis; it is a combination of clinical history and laboratory findings.

FSH and LH are the cornerstone tests. FSH above 25 IU/L on two separate measurements at least four to six weeks apart, in the context of amenorrhea or oligomenorrhea, establishes the diagnosis. LH is also elevated. The FSH:LH ratio and the absolute values are both informative: in autoimmune oophoritis, FSH can be strikingly high while some follicular activity persists on ultrasound, creating a confusing picture. It is important to confirm with a second sample because FSH can transiently rise in women who are not in POI.

Estradiol is low, typically below 50 pg/mL and often below 20 pg/mL in established POI. Low estradiol in the context of elevated FSH confirms the ovary is not responding to pituitary stimulation.

Anti-Müllerian hormone (AMH) is produced by small antral follicles and is the best marker of remaining ovarian reserve. In POI, AMH is extremely low or undetectable. While not required for the diagnosis, AMH helps quantify the follicular pool and can be useful in counseling about the likelihood of spontaneous ovulation.

Pregnancy test must be done at diagnosis. Amenorrhea can be the first sign of pregnancy, and FSH is suppressed in pregnancy, so a positive hCG test immediately redirects the workup.

Karyotype is recommended for all women with POI under age 35 to detect Turner syndrome and other sex chromosome abnormalities. Mosaicism (partial Turner, 45,X/46,XX) may be missed on a standard blood karyotype and sometimes requires buccal swab or skin fibroblast analysis if clinical suspicion is high.

FMR1 premutation testing should be offered to all women with unexplained POI regardless of age or family history, because FMR1 premutations are frequently de novo and family history of fragile X syndrome may not be known. A genetic counselor should be involved when a premutation is found.

Adrenal antibodies — specifically anti-21-hydroxylase antibodies — identify women with autoimmune POI who are at risk of developing Addison's disease. Positive results require annual monitoring with morning cortisol levels or, when cortisol is borderline, a formal ACTH stimulation test.

Thyroid function and antibodies (TSH, free T4, TPO antibodies, and thyroglobulin antibodies) should be checked at diagnosis and monitored annually given the high prevalence of thyroid autoimmunity in POI.

Bone density (DEXA scan) should be performed at diagnosis to establish a baseline and guide the urgency of HRT initiation. Repeat scanning at two to three year intervals assesses the response to treatment.

Back to Table of Contents

Hormone Replacement Therapy — Why It Differs from Postmenopausal HRT

One of the most damaging consequences of the 2002 Women's Health Initiative (WHI) study was its effect on HRT prescribing for young women with POI. The WHI showed that oral conjugated equine estrogen combined with medroxyprogesterone acetate (MPA) increased the risk of breast cancer and cardiovascular events in postmenopausal women with a mean age of 63. Many physicians, patients, and families extrapolated these findings to all hormone therapy in all women — including those with POI. This extrapolation is incorrect and potentially dangerous.

The critical difference is the baseline. A 30-year-old woman with POI has profoundly less estrogen than any of her peers. When she takes HRT, she is restoring estrogen to a level her body should naturally have, not adding estrogen on top of a normal age-appropriate baseline. The risks associated with the WHI applied to older women who had been estrogen-sufficient for 50 years and were now receiving exogenous hormones in addition to their endogenous (declining but not absent) production. Those findings do not translate to young women with POI.

International guidelines from ESHRE (European Society of Human Reproduction and Embryology), the British Menopause Society, and the International Menopause Society all issue the same recommendation: women with POI should be offered HRT and should continue it until approximately age 51 — the average age of natural menopause — unless there is a specific contraindication such as estrogen receptor-positive breast cancer. The risks of long-term estrogen deficiency in young women — accelerated bone loss, cardiovascular disease, cognitive decline, and increased all-cause mortality — are greater than the risks of physiological HRT.

Many women with POI are instead prescribed the combined oral contraceptive pill (COC), which offers the advantage of contraception. However, the standard COC contains ethinyl estradiol at doses lower than the physiological estrogen in a premenopausal woman, and it does not fully substitute for HRT in terms of bone and cardiovascular protection. Women who require contraception may use a COC, but for women whose primary concern is long-term health, standard HRT formulations are preferred.

Back to Table of Contents

Estrogen, Progesterone, and Testosterone Specifics

Estrogen route and dose matter substantially. Transdermal estradiol — delivered as a twice-weekly patch or a daily gel rubbed onto the skin — is preferred over oral estrogen for cardiovascular safety. Oral estrogen undergoes first-pass metabolism in the liver, stimulating hepatic synthesis of clotting factors, C-reactive protein, and renin substrate, effects that increase the risk of venous thromboembolism and stroke. Transdermal estradiol bypasses the liver and avoids these effects. The standard dose for POI is estradiol 100 micrograms per 24 hours via patch, which approximates early-to-mid follicular phase estradiol levels in a premenopausal woman. Young women often need higher doses than older postmenopausal women to control vasomotor symptoms and maintain bone density.

Progestogen is required in women with a uterus to protect the endometrium from unopposed estrogen stimulation, which would otherwise increase the risk of endometrial hyperplasia and cancer. Micronized progesterone (brand names Utrogestan or Prometrium) is the preferred agent. Given at 200 mg for 12 days per month in a cyclical regimen, it produces a withdrawal bleed and provides endometrial protection while avoiding the adverse lipid and cardiovascular effects associated with synthetic progestins such as MPA. An alternative for women who find the cyclical bleed burdensome or inconvenient is the levonorgestrel-releasing intrauterine system (Mirena IUS), which provides local endometrial protection with minimal systemic progestogen exposure.

Testosterone is often overlooked in POI management despite being important. Women's ovaries normally produce roughly half of total testosterone; with ovarian failure, this contribution is lost, creating androgen deficiency alongside estrogen deficiency. Low libido, persistent fatigue, lack of motivation, and reduced sense of well-being that do not fully resolve with estrogen replacement may reflect insufficient testosterone. No licensed female testosterone product exists in many countries, so off-label use of male testosterone preparations at approximately one-tenth of the male dose, or use of compounded testosterone cream, is common. Monitoring with blood testosterone levels — targeting the mid-normal premenopausal female range — prevents inadvertent excess.

DHEA (dehydroepiandrosterone), an adrenal androgen that the body converts into testosterone and estrogen, has been studied in POI. Some evidence suggests that oral DHEA at 25 to 50 mg daily may modestly improve ovarian function markers and quality of life, although evidence from randomized trials remains limited. Vaginal DHEA (prasterone, brand name Intrarosa) acts locally in the vaginal epithelium, improving genitourinary symptoms with minimal systemic absorption, and is a useful option for women whose genitourinary symptoms are not adequately addressed by systemic estrogen alone.

Bone health management begins with ensuring adequate estrogen replacement. Calcium (1000–1200 mg/day from food and supplements combined) and vitamin D (1000–2000 IU/day) are important adjuncts. Weight-bearing exercise — walking, jogging, resistance training — stimulates bone formation. Bisphosphonates such as alendronate are not routinely needed when HRT is adequate; they are reserved for women with documented osteoporosis who have a contraindication to estrogen or whose bone density continues to decline despite adequate HRT.

Back to Table of Contents

Fertility Options and Family Planning

For most women with POI, the greatest immediate concern after the diagnosis is fertility. It is important to be honest and compassionate: the majority of women with established POI will not conceive with their own eggs, but several realistic pathways exist.

Egg donation IVF is the most effective fertility treatment for women with POI. Because the POI uterus and endometrium are normal in structure and retain the ability to respond to exogenous estrogen and progesterone, success rates with donor eggs are similar to or higher than those seen in age-matched IVF cycles using the donor's own eggs. Cumulative live birth rates of 40 to 60 percent per treatment cycle are reported in well-run programs. The uterus is prepared with estradiol and progesterone to mimic the natural implantation window, and embryos created from donor eggs are transferred. For women who accept egg donation, this is a reliable path to parenthood that should be discussed early.

Spontaneous pregnancy occurs in approximately 5 to 10 percent of women with POI, reflecting the intermittent follicular activity that distinguishes POI from complete ovarian failure. This cannot be predicted or reliably induced, but it is real. For women who wish to maximize the chance of detecting spontaneous ovulation, periodic ultrasound monitoring and LH surge testing can identify windows of opportunity. Women who do not wish to conceive must understand that contraception is required — POI does not equal infertility.

Fertility preservation before iatrogenic POI is the clearest scenario for proactive action. Women facing gonadotoxic chemotherapy or pelvic radiation should be referred urgently — within days to one to two weeks — to a reproductive endocrinologist to discuss oocyte cryopreservation (egg freezing) or, if partnered, embryo cryopreservation. These methods require an IVF stimulation cycle lasting approximately 10 to 14 days before chemotherapy begins. When timing does not permit stimulation, ovarian tissue cryopreservation may be offered; the tissue is removed laparoscopically, frozen, and can be later retransplanted to restore natural ovarian function or used in an IVF cycle. Both options are increasingly covered by insurance in jurisdictions with fertility preservation mandates for cancer patients.

Other family-building paths include embryo adoption (using donor embryos rather than a known egg donor), surrogacy if uterine function is also impaired, and adoption. These should be presented as genuinely valid paths to parenthood, not as consolation prizes. Many women find that the act of being offered comprehensive information about all options — rather than simply being told they are unlikely to conceive — restores a sense of agency at a moment when everything feels outside their control.

Back to Table of Contents

Psychological Support and Long-Term Wellbeing

The psychological sequelae of POI are severe and systematically underaddressed. Studies show that women with POI report significantly worse quality of life, higher rates of depression and anxiety, and greater distress than age-matched controls — and that the emotional burden of the diagnosis often exceeds the physical symptoms in the early months after diagnosis. Yet most women report that their healthcare providers spent little or no time discussing the psychological impact.

Grief is the most appropriate framework for what many women experience. The losses are real: the loss of a reproductive timeline that was assumed; the loss of an easy path to genetic parenthood; the loss of the certainty of going through this experience alongside peers. For some women there is also grief over the loss of a sense of bodily normalcy and a fear of accelerated aging. This grief can involve all the stages clinicians recognize — shock and denial, anger, bargaining (over fertility treatments), depression, and eventually acceptance — and it does not move on a neat schedule.

Peer support has consistently been identified in research as one of the most helpful resources for women with POI. Connecting with other women who understand the experience — which friends, family, and even well-meaning physicians often do not — reduces isolation and provides practical knowledge. Organizations such as the Daisy Network (UK), the International Premature Ovarian Insufficiency Association, and Resolve (focused on infertility in the US) offer peer forums, informational resources, and in some cases counseling referrals.

Individual or couples counseling — specifically with a therapist experienced in chronic illness, infertility, or women's health — can help process grief, address relationship and sexual function concerns, and build coping strategies for managing a chronic condition that requires lifelong monitoring and treatment. The relationship impact of POI can be significant: partners may not know how to respond; the couple's shared plans for parenthood are disrupted; and sexual difficulties from genitourinary symptoms and low libido create distance that both partners often suffer in silence.

Long-term wellbeing with POI also involves maintaining engagement with healthcare. Annual thyroid function tests, adrenal monitoring if indicated, periodic DEXA scanning, cardiovascular risk assessment, and regular review of HRT adequacy are all part of the long-term picture. Women who remain on appropriate HRT through to the natural age of menopause have cardiovascular and bone outcomes equivalent to women who experienced menopause at the expected age. The prognosis with good care is excellent; the prognosis without it is substantially worse. Patients who advocate for themselves — asking for FSH testing when cycles become irregular, pushing for genetic testing when POI is confirmed, and insisting on adequate HRT — get better outcomes.

Back to Table of Contents

Key Research Papers

  1. Webber L et al (2016). ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod, 31(5):926–937. PMID 26908840. doi:10.1093/humrep/dew027
  2. Shelling AN (2010). Premature ovarian failure. Reproduction, 140(5):633–641. PMID 20716613. doi:10.1530/REP-10-0097
  3. Coulam CB, Adamson SC, Annegers JF (1986). Incidence of premature ovarian failure. Obstet Gynecol, 67(4):604–606. PMID 3960433.
  4. Persani L et al (2016). Evidence for a major role of FMR1 in premature ovarian insufficiency. Front Genet, 7:59. PMID 27148344. doi:10.3389/fgene.2016.00059
  5. Husebye ES et al (2021). Autoimmune Addison disease. Nat Rev Dis Primers, 7(1):30. PMID 33927199. doi:10.1038/s41572-021-00263-6
  6. Kalantaridou SN et al (2004). Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab, 89(8):3907–3913. PMID 15292328. doi:10.1210/jc.2004-0015
  7. Sullivan SD, Sarrel PM, Nelson LM (2016). Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril, 106(7):1588–1599. PMID 27912889. doi:10.1016/j.fertnstert.2016.09.046
  8. Okeke T, Anyaehie U, Ezenyeaku C (2013). Premature menopause. Ann Med Health Sci Res, 3(1):90–95. PMID 23634331. doi:10.4103/2141-9248.109458
  9. Van Kasteren YM, Schoemaker J (1999). Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update, 5(5):483–492. PMID 10582785. doi:10.1093/humupd/5.5.483
  10. De Vos M, Devroey P, Fauser BC (2010). Primary ovarian insufficiency. Lancet, 376(9744):911–921. PMID 20708256. doi:10.1016/S0140-6736(10)60355-8
  11. Santoro N (2003). Mechanisms of premature ovarian failure. Ann Endocrinol (Paris), 64(2):87–92. PMID 12761531.
  12. Groff AA et al (2005). Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril, 83(6):1734–1741. PMID 15950650. doi:10.1016/j.fertnstert.2004.11.067

Back to Table of Contents

Connections

Back to Table of Contents